Lucid Diagnostics Announces Proposed Public Offering of Common Stock

NEW YORK, April 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced its intention to offer shares of common stock through an underwritten public offering. The Company also plans to grant the underwriters a 45-day option to purchase additional shares of common stock. Proceeds from the offering are expected to support working capital and general corporate purposes. Completion of the offering remains subject to market conditions, with no assurance regarding its timing, size, or terms.

Read more at prnewswire.com